Cancer Statistics, 2010. now online (U.S.)

Statistics

Now Published Online!
Cancer Statistics, 2010
View the Abstract or read the full-text PDF today!

Ovary incident rate: 21,880  

Ovary deaths  13,850

http://cacancerjournal.org/

in research: Magnetic nanoparticles remove ovarian cancer cells from the abdominal cavity

(Nanowerk News) A major complicating factor in the treatment of ovarian cancer is that malignant cells are often shed into the patient's abdominal cavity. These cells can then spread to other tissues, seeding new tumors that make effective therapy difficult. To overcome this problem, researchers at the Georgia Institute of Technology created magnetic nanoparticles that can selectively bind to and remove ovarian tumor cells from abdominal cavity fluid. John F. McDonald led the research team that reported their work in the journal Nanomedicine ("Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles").

Research by other investigators had identified a protein known as EphA2 as a highly selective marker for free-floating ovarian cancer cells. Dr. McDonald and his collaborators coated magnetic cobalt-iron oxide nanoparticles with a molecular mimic of the natural ligand for this protein, a molecule known as ephrin-A1, to serve as a trap for ovarian cancer cells floating in ascites fluid, the liquid found in the intestinal cavity. The idea behind this approach is that the nanoparticles could be added to ascites fluid and then trapped with a magnetic, removing any ovarian cancer cells that had bound to the eprhin-A1 mimic.

They first tested their nanoparticles using ascites fluid from mice with human ovarian tumors and found that they could trap free-floating tumor cells using magnetic separation. They then repeated this experiment using ascites fluid obtained from four women with ovarian cancer, and again showed that they could remove all of the EphA2-positive cells from the intestinal fluid samples. The researchers suggest that these nanoparticles could be used in a system that removes ascites fluid from the intestinal cavity, using a relatively non-invasive method akin to dialysis, in conjunction with standard ovarian cancer therapy.

Source: National Cancer Institute

repost: full text Angiogenesis Inhibitors: Current Strategies and Future Prospects

INHIBITOR OTHER NAMES INHIBITS Axitinib AG013736 VEGFR, PDGFR, and c-kit Canertinib CI-1033 EGFR, HER2, HER3, and HER4 Cediranib Recentin, AZD2171 VEGFR, PDGFR-, and c-kit Dasatinib Sprycel, BMS-354825 Abl, Src, and Tec Erlotinib Tarceva, OSI-774 EGFR/HER1 Gefitinib Iressa EGFR/HER1 Imatinib Gleevec, STI571 Abl, PDGFR, and c-kit Lapatinib Tykerb, GW-572016 EGFR and HER2 Leflunomide Arava, SU101 PDGFR (EGFR and FGFR) Motesanib AMG 706 VEGFR, PDGFR, and c-kit Neratinib HKI-272 EGFR and HER2 Nilotinib Tasigna Abl, PDGFR, and c-kit Pazopanib Armala, GW786034 VEGFR, PDGFR- and -, and c-kit Regorafenib BAY 73-4506 VEGFR-2 and Tie-2 Semaxinib SU5416 VEGFR Sorafenib Nexavar, BAY 43-9006 Raf, VEGFR-2 and -3, PDGFR-, and c-kit Sunitinib Sutent, SU11248 VEGFR, PDGFR, Flt-3, c-kit, RET, and CSF-1R Tandutinab MLN518, CT53518 PDGFR, Flt-3, and c-kit Toceranib Vandetanib Zactima, ZD6474 VEGFR-2, PDGFR-, EGFR, and RET Vatalanib PTK787 VEGFR, PDGFR-, and c-kit

Caring Voices upcoming (moderated) chat sessions

The Big Flap About Pathway Genomics and Walgreen's: Topol on Genomics

A few weeks ago, Pathway Genomics, a consumer genomics company, had planned to have its saliva kits at all US Walgreen's drug stores. The FDA put a stop to it. Congress is now investigating the matter. What is going on here?
http://www.nytimes.com/2010/06/12/health/12genome.html?scp=1&sq=pathway%20genomics&st=cse

Search of: parp | Open Studies - List Results - ClinicalTrials.gov

Found 33 studies with search of: parp | Open Studies

Second primary cancers following borderline ovarian tumors (abstract)

Note: (in the abstract) the onset of a  basal cell carcinoma of the eyelid (genetics?)

CONCLUSIONS: These findings do not suggest increased risk of subsequent cancers in patients with BOT. However, population-based studies are needed for evaluating exact risk of developing second primary malignancies in women with BOTs

A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gyne

Blogger's Note: in the absence of full access to the article, this conclusion 'needs more research'


"CONCLUSIONS:: Pyridoxine as administered in the current study did not prevent HFS in patients who received PLD. It is possible that QOL is not compromised in patients with HFS because they may have increased social well being while coping with their disease."

6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance

"Altogether, our data show that 6TG efficiently kills BRCA2-defective tumors and suggest that 6TG may be effective in the treatment of advanced tumors that have developed resistance to PARP inhibitors or platinum-based chemotherapy. Cancer Res; 70(15); OF1-9. (c)2010 AACR."

abstract: Clinical syndromes associated with ovarian neoplasms: a comprehensive review

Radiographics. 2010 Jul-Aug;30(4):903-19.

Functional ovarian neoplasms have unique clinical manifestations related to hormone overproduction and may give rise to a broad spectrum of clinical syndromes.

Sex cord-stromal tumors, the most common functional ovarian neoplasms, are associated with either hyperestrogenism (as in granulosa cell tumor and thecoma) or hyperandrogenism (as in Sertoli-Leydig cell tumor and Leydig cell tumor). Other, less common ovarian neoplasms that may have endocrine or nonendocrine syndromic manifestations include germ cell tumors associated with the excessive production of human chorionic gonadotropin (eg, choriocarcinoma, dysgerminoma), monodermal teratomas (eg, carcinoid tumor, struma ovarii) associated with carcinoid syndrome and hyperthyroidism, and primary epithelial ovarian cancers associated with paraneoplastic syndromes.

The application of diagnostic algorithms based on patient demographic information, clinical manifestations, laboratory findings, and cross-sectional imaging features may help identify ovarian neoplasms in complex clinical settings.